We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+32.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$435M
AUM Growth
+$90.3M
(+26%)
Cap. Flow
+$69M
Cap. Flow
% of AUM
15.87%
Top 10 Holdings %
Top 10 Hldgs %
46.41%
Holding
58
New
21
Increased
13
Reduced
6
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$16.9M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$15.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$14.7M |
| 4 |
PTC Therapeutics
PTCT
|
+$14M |
| 5 |
Prothena Corp
PRTA
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$22M |
| 2 |
CELG
Celgene Corp
CELG
|
+$20.3M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$15.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$14.4M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
| $38.6M | 8.88% |
1,200,000
+106,200
| +10% | +$3.92M |
|
|
CBST
2
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $21.9M | 5.05% |
300,000
-100,000
| -25% | -$7.46M |
|
3
Puma Biotechnology
PBYI
$398M
| $21.6M | 4.97% |
207,500
+7,500
| +4% | +$882K |
|
|
4
BioMarin Pharmaceuticals
BMRN
$11.9B
| $20.5M | 4.71% |
300,000
+200,000
| +200% | +$14.7M |
|
|
RCPT
5
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $18.9M | 4.34% |
450,000
+100,000
| +29% | +$4.3M |
|
|
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
| $18M | 4.13% |
2,000,000
-850,000
| -30% | -$7.73M |
|
|
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $16.5M | 3.79% |
+50,000
| New | +$16.9M |
|
8
Arrowhead Research
ARWR
$12.1B
| $16.4M | 3.78% |
1,000,000
+4,500
| +0.5% | +$79K |
|
|
IDIX
9
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $15.1M | 3.47% |
2,500,000
-425,000
| -15% | -$2.96M |
|
|
10
PTC Therapeutics
PTCT
$6.18B
| $14.4M | 3.31% |
550,000
+521,200
| +1,810% | +$14M |
|
|
11
Jazz Pharmaceuticals
JAZZ
$16.1B
| $13.9M | 3.19% |
+100,000
| New | +$15.1M |
|
|
12
Prothena Corp
PRTA
$448M
| $13.4M | 3.08% |
+350,000
| New | +$11.3M |
|
13
DexCom
DXCM
$29B
| $12.4M | 2.85% |
1,200,000
| – | – |
|
14
BioCryst Pharmaceuticals
BCRX
$2.42B
| $12.4M | 2.84% |
1,168,000
+900,000
| +336% | +$9.6M |
|
15
Merck
MRK
$322B
| $11.4M | 2.61% |
+209,600
| New | +$10.9M |
|
|
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $10.8M | 2.49% |
600,000
+433,800
| +261% | +$8.36M |
|
17
Talphera
TLPH
$68M
| $9.01M | 2.07% |
37,500
| – | – |
|
|
SRNE
18
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $8.97M | 2.06% |
+700,000
| New | +$7.75M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $8.84M | 2.03% |
300,000
| – | – |
|
20
Alkermes
ALKS
$8.11B
| $8.82M | 2.03% |
+200,000
| New | +$9.52M |
|
21
Karyopharm Therapeutics
KPTI
$155M
| $8.65M | 1.99% |
18,667
+12,000
| +180% | +$6.08M |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.31M | 1.91% |
120,000
+700
| +0.6% | +$51.4K |
|
|
NSTG
23
DELISTED
NanoString Technologies, Inc.
NSTG
| $8.26M | 1.9% |
+400,000
| New | +$7.62M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $8.22M | 1.89% |
1,750,000
| – | – |
|
|
CBIO
25
Crescent Biopharma
CBIO
$546M
| $7.67M | 1.76% |
+4,694
| New | +$5.68M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q1 2014 Portfolio in Review
As of Q1 2014, Cormorant Asset Management held 58 positions worth $435M, up 26% from $345M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Cormorant Asset Management deployed $69M of net new capital in Q1 2014, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 63% a quarter earlier.
On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.5M trimmed.
- Cormorant Asset Management's largest Q1 2014 buy was Intercept Pharmaceuticals, Inc.: 50,000 shares worth $16.5M.
- Cormorant Asset Management added most to BioMarin Pharmaceuticals in Q1 2014, an estimated $14.7M increase.
- Cormorant Asset Management's biggest Q1 2014 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.5M.
- Cormorant Asset Management fully exited Keryx Biopharmaceuticals Inc in Q1 2014, selling an estimated $22M.
- Cormorant Asset Management's ten largest holdings make up 46% of its $435M portfolio in Q1 2014.
- Cormorant Asset Management opened 21 new positions and closed 12 in Q1 2014.
- Cormorant Asset Management's portfolio value rose 26% quarter-over-quarter to $435M.
Based on Cormorant Asset Management's 13F filing for Q1 2014, filed 15 May 2014.